NCT02563925View on ClinicalTrials.gov

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

NACompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

September 18, 2015

Primary Completion Date

July 14, 2021

Study Completion Date

July 14, 2021

Conditions

Metastatic Breast Cancer

Interventions

RADIATION

Brain radiotherapy or Stereotactic Radiosurgery

DRUG

Tremelimumab

DRUG

HER2 directed therapy

DRUG

Durvalumab

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

MedImmune LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER